Table 3 Comparison of R1 and R2 ratings
Domain | No. of item^ | R1 | R2 | z | p-value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Median score | Q1 | Q3 | Critically important | Mean | SD | Median score | Q1 | Q3 | Critically important | ||||
Patient educational material | |||||||||||||||
1. Knowledge of the disease | 1 | 8.42 | 0.98 | 9.00 | 8.00 | 9.00 | 97.7% | 8.41 | 0.91 | 9.00 | 8.00 | 9.00 | 97.0% | 0.000 | 1.000 |
2. Symptoms assessment | 3 | 8.14 | 1.13 | 8.33 | 7.50 | 9.00 | 90.8% | 8.30 | 0.91 | 8.75 | 7.75 | 9.00 | 95.5% | − 1.000 | 0.317 |
3. Diagnosis | 1 | 7.42 | 1.68 | 8.00 | 6.50 | 9.00 | 75.0% | 7.94 | 1.52 | 8.00 | 7.25 | 9.00 | 91.4% | 0.000 | 1.000 |
4. A) Allergen identification and avoidance | 9 | 7.87 | 1.39 | 8.33 | 7.11 | 9.00 | 86.4% | 8.20 | 1.21 | 8.80 | 7.80 | 9.00 | 93.8% | − 1.000 | 0.317 |
B) Two items of allergen identification and avoidance§ | 2 | 6.90 | 2.01 | 7.50 | 5.00 | 9.00 | 64.8% | 8.18 | 1.09 | 8.50 | 7.50 | 9.00 | 92.9% | − 1.000 | 0.317 |
5. Nasal corticosteroid | 6 | 7.95 | 1.45 | 8.33 | 7.33 | 9.00 | 89.4% | 8.23 | 0.99 | 8.71 | 7.71 | 9.00 | 92.2% | − 1.000 | 0.317 |
a. Technique of priming | 4 | 8.48 | 0.89 | 9.00 | 8.13 | 9.00 | 92.9% | 8.22 | 1.18 | 9.00 | 7.88 | 9.00 | 90.9% | 0.000 | 1.000 |
b. Before administration | 1 | 8.16 | 1.76 | 9.00 | 8.00 | 9.00 | 90.9% | 8.03 | 1.53 | 9.00 | 7.00 | 9.00 | 91.2% | 0.000 | 1.000 |
c. During administration | 1 | 8.42 | 0.99 | 9.00 | 8.00 | 9.00 | 93.2% | 8.27 | 1.13 | 9.00 | 8.00 | 9.00 | 94.1% | 0.000 | 1.000 |
6. Antihistamine | 3 | 7.98 | 1.41 | 8.67 | 7.33 | 9.00 | 81.8% | 8.21 | 1.23 | 9.00 | 8.00 | 9.00 | 90.3% | − 1.000 | 0.317 |
7. Decongestant | 2 | 7.79 | 1.72 | 8.50 | 7.00 | 9.00 | 83.0% | 8.23 | 1.47 | 9.00 | 8.00 | 9.00 | 95.6% | − 1.000 | 0.317 |
8. Nasal douche (saline) | 5 | 8.03 | 1.22 | 8.30 | 7.10 | 9.00 | 87.3% | 8.23 | 1.38 | 9.00 | 8.00 | 9.00 | 93.3% | − 1.000 | 0.317 |
9. What to do when symptom flare | 3 | 8.18 | 1.21 | 8.83 | 7.50 | 9.00 | 90.2% | 8.31 | 0.86 | 8.50 | 8.00 | 9.00 | 96.0% | − 1.000 | 0.317 |
10. Consequences of non-adherence | 2 | 8.27 | 1.00 | 9.00 | 8.00 | 9.00 | 92.1% | 8.31 | 1.12 | 9.00 | 8.00 | 9.00 | 93.8% | 0.000 | 1.000 |
Pharmacist counselling scopes and algorithm | |||||||||||||||
1. Patient selection criteria | 1 | 7.88 | 1.37 | 8.00 | 7.25 | 9.00 | 88.1% | 8.13 | 0.99 | 8.00 | 8.00 | 9.00 | 90.6% | 0.000 | 1.000 |
2. Symptoms assessment | 1 | 8.00 | 1.29 | 8.00 | 7.00 | 9.00 | 88.4% | 8.03 | 1.22 | 8.00 | 7.50 | 9.00 | 93.8% | 0.000 | 1.000 |
3. Patients’ quality of life | 1 | 8.23 | 1.01 | 9.00 | 8.00 | 9.00 | 87.5% | 8.23 | 1.15 | 9.00 | 8.00 | 9.00 | 87.5% | 0.000 | 1.000 |
4. New user to nasal spray | 1 | 8.57 | 0.70 | 9.00 | 8.00 | 9.00 | 100.0% | 8.55 | 0.72 | 9.00 | 8.00 | 9.00 | 96.9% | 0.000 | 1.000 |
5. Existing nasal spray users | 1 | 8.55 | 0.71 | 9.00 | 8.00 | 9.00 | 97.7% | 8.19 | 1.68 | 9.00 | 8.00 | 9.00 | 90.6% | 0.000 | 1.000 |
6. Teach patients the alert sign | 1 | 8.55 | 0.77 | 9.00 | 8.00 | 9.00 | 97.7% | 8.47 | 1.00 | 9.00 | 8.00 | 9.00 | 100.0% | 0.000 | 1.000 |
7. Follow-up pharmaceutical care | 1 | 8.26 | 1.17 | 9.00 | 8.00 | 9.00 | 90.7% | 8.29 | 1.22 | 9.00 | 8.00 | 9.00 | 96.9% | 0.000 | 1.000 |
8. Patient discharge | 1 | 8.23 | 1.16 | 9.00 | 7.00 | 9.00 | 93.0% | 8.55 | 0.62 | 9.00 | 8.00 | 9.00 | 100.0% | 0.000 | 1.000 |
9. Algorithm of pharmaceutical care | 1 | 8.13 | 1.03 | 8.00 | 8.00 | 9.00 | 92.3% | 8.50 | 0.95 | 9.00 | 8.00 | 9.00 | 96.3% | − 1.000 | 0.317 |
10. Stepwise treatment approach | 1 | 8.00 | 1.55 | 9.00 | 8.00 | 9.00 | 86.5% | 8.40 | 1.13 | 9.00 | 8.00 | 9.00 | 93.5% | 0.000 | 1.000 |
11. Pharmacotherapy agents | 3 | 8.28 | 0.99 | 8.88 | 8.00 | 9.00 | 92.8% | 8.45 | 0.79 | 9.00 | 8.00 | 9.00 | 98.0% | − 1.000 | 0.317 |